In Taiwan’s drug registration, **New Chemical Entities (NCEs)** are innovative drugs with new active ingredients not previously approved, requiring extensive clinical trials and a thorough TFDA review. **Generics**, by contrast, replicate existing drugs, needing only bioequivalence studies to demonstrate similar efficacy and safety, allowing for a faster and simpler approval process.
